Current developments in neurology, Part II: Advances in the pharmacotherapy of Alzheimer disease, Parkinson's disease, and stroke.
Disorders of the central nervous system provide innumerable challenges to the clinician. Often the underlying pathophysiology is not completely understood, thus preventing the design of treatment strategies aimed at correcting the underlying process. In this decade of the brain, basic science research combined with difficult but necessary clinical trials may answer some of these seemingly over-whelming questions for these devastating illnesses.
Gidal
B E
BE
School of Pharmacy, University of Wisconsin, Madison, WI 53706, USA.
Crismon
M L
ML
Wagner
M L
ML
Fagan
S C
SC
Privitera
M D
MD
Dalmady-Israel
C
C
Graves
N M
NM
D000544:Alzheimer Disease / Q000188:drug therapy*; D000925:Anticoagulants / Q000627:therapeutic use; D001058:Apomorphine / Q000494:pharmacology; D001241:Aspirin / Q000627:therapeutic use; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000517:prevention & control; D018678:Cholinergic Agents / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000494:pharmacology; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology; D010300:Parkinson Disease / Q000188:drug therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D013619:Tacrine / Q000627:therapeutic use
D000925:Anticoagulants; D018678:Cholinergic Agents; D018491:Dopamine Agonists; D008996:Monoamine Oxidase Inhibitors; D010975:Platelet Aggregation Inhibitors; D013619:Tacrine; D001058:Apomorphine; D001241:Aspirin